Activities (5,000,000) - ------------ ------------ Cash Flows From Financing Activities: Proceeds from common stock option exercises - 31,267 Merger, net (3,831,357) Net proceeds from registered direct offerings 13,803,684 13,798,183 ------------ ------------ Net Cash Provided By Financing Activities 9,972,327 13,829,450 ------------ ------------ Net Change in Cash and Cash Equivalents (23,229,048) (15,230,762) Cash and Cash Equivalents -- Beginning of Year 26,480,928 41,711,690 ------------ ------------ Cash and Cash Equivalents -- End of Year $ 3,251,880 $ 26,480,928 ============ ============ Supplemental Disclosures of Cash Flow Information and Non-cash Activities: IPR&D Milestones included in License Payable $ 28,400,000 $ - Prepaid Manufacturing transferred to Inventory $ 6,134,895 $ - Reflects a 1-for-25 reverse stock split effective November 25, 2024.
View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-inc-reports-fiscal-full-year-2024-financial-results-and-provides-business-update-302339718.html
SOURCE Citius Pharmaceuticals, Inc.
(END) Dow Jones Newswires
December 27, 2024 17:00 ET (22:00 GMT)
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。